A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus

Lignende værker

• An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
  af: Eisenberg, RA, et al.
  Udgivet: (2004)
• Efficacy of rituximab (anti‐CD20) for refractory systemic lupus erythematosus involving the central nervous system
  af: Tokunaga, Mikiko, et al.
  Udgivet: (2007)
• Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
  af: Quelhas da Costa, Rita, et al.
  Udgivet: (2018)
• Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
  af: Martínez-Pérez, R, et al.
  Udgivet: (2010)
• Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
  af: Reddy, Venkat, et al.
  Udgivet: (2015)